Business Segments · Payments for Restructuring
North American Pharmaceutical — Payments for Restructuring
McKesson North American Pharmaceutical — Payments for Restructuring decreased by 50.0% to $1.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $2.00M to $1.00M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ4 2026May 8, 2026
Rolls up toPayments for Restructuring
How to read this metric
High payments indicate active organizational transformation, while declining payments suggest the completion of restructuring initiatives.
Detailed definition
Actual cash outflows related to the implementation of restructuring programs within the North American pharmaceutical se...
Peer comparison
Commonly tracked by analysts to assess the cash impact of corporate efficiency programs and turnaround strategies.
Metric ID:
mck_segment_north_american_pharmaceutical_payments_for_restructuringHistorical Data
5 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q4 '26 | |
|---|---|---|---|---|---|
| Value | $2.00M | $2.00M | $2.00M | $2.00M | $1.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -50.0% |
| YoY Change | — | — | — | — | -50.0% |
Range$1.00M – $2.00M
CAGR-50.0%
Avg YoY Growth-50.0%
Median YoY Growth-50.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — payments for restructuring?
- McKesson (MCK) reported north american pharmaceutical — payments for restructuring of $1.00M in Q1 2026.
- How has McKesson's north american pharmaceutical — payments for restructuring changed year-over-year?
- McKesson's north american pharmaceutical — payments for restructuring decreased by 50.0% year-over-year, from $2.00M to $1.00M.
- What does north american pharmaceutical — payments for restructuring mean?
- Cash spent on executing restructuring or organizational changes within the pharmaceutical segment.